Third-party-funded project
Title:
Clopidogrel: Mechanism of action and role as antiplatelet / anti-inflammatory drug
Project management at the University of Würzburg:
Participating scientists:
Abstract:
The central aspect and goal of our project was to enhance the understanding of the physiological / pathophysiological / pharmacological roles of human platelet ADP receptors and the mechanisms of Clopidogrel action. The data obtained in this project, which was supported by Sanofi-Synthelabo and Bristol-Myers Squibb, contributed to the 3-receptor concept of purinergic signaling in human platelets and identified the P2Y12 ADP receptor as molecular target for the antiplatelet drugs ticlopidine and clopidogrel. In several resulting publications, the pharmacology of platelet ADP receptors and their regulation/inhibition by Clopidogrel were described.
Key words:
Clopidogrel
Ticlopidine
Purinergic receptors
Antiplatelet drugs
Projekt period:
from 01.2000 to 06.2002
Funding institution:
Wirtschaftsunternehmen ,Granting date: 21.01.2000
Publications:
- Aktas B, Honig-Liedl P, Walter U, Geiger J.
(2002). Inhibition of platelet P2Y12 and alpha2A receptor signaling by cGMP-dependent protein kinase. Biochem pharmacol, 64: 433-9, (scientific article)
- Schwarz UR, Walter U, Eigenthaler M.
(2001). Taming platelets with cyclic nucleotides. Biochem Pharmacol 62, 1153-1161, (scientific article)
- Schwarz UR, Kobsar AL, Koksch M, Walter U, Eigenthaler M.
(2000). Inhibition of agonist-induced p42 and p38 mitogen-activated protein kinase phosphorylation and CD40 Ligand/P-Selectin Expression by Cyclic Nucleotide-Regulated Pathways in Human Platelets. . Biochem Pharmacol 60, 1399 ? 1407, (scientific article)
- Schwarz UR, Geiger J, Walter U, Eigenthaler M.
(1999). Flow cytometry analysis of intracellular protein phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets. . Thromb Haemost 82. 1145-1152, (scientific article)
- Geiger J, Brich J, Hönig-Liedl P, Eigenthaler M, Schanzenbächer P , Herbert JM and Walter U.
(1999). Specific Impairment Of Human Platelet P2YAC ADP Receptor-Mediated Signaling By The Antiplatelet Drug Clopidogrel. Arterioscler Thromb Vasc Biol 19 , 2007-2011, (scientific article)
- Geiger J, Hönig-Liedl P, Schanzenbächer P and Walter U.
(1998). Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors. Eur J Pharmacol 351, (scientific article)
Links:
Sanofi-Synthelabo GmbH
Bristol-Myers Squibb GmbH
